

10/516079

FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006

=> index biosci
FILE 'DRUGMONO2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE
ENTRY
0.21
TOTAL
SESSION
0.21

INDEX 'ADISCTI', ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHAS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONO2, DRUGU, ENBAL, EMBASE, ... ENTERED AT 03:09:52 ON 09 JUN 2006

68 FILES IN THE FILE LIST IN STINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s chlorotoxin
3 FILE ADISINSIGHT
5 FILE AGRICOLA
1 FILE ANABSTR
32 FILE BIOSIS
3 FILE BIOTECHAS
3 FILE BIOTECHDS
8 FILE BIOTECHNO
11 FILE CABA
41 FILE CAPLUS
1 FILE CEABA-VTB
8 FILE CIN
2 FILE DDFU
235 FILE DGENE
2 FILE DISSABS
2 FILE DRUGU
28 FILE EMBASE
22 FILE EMBIOBASE
1 FILE GENBANK
13 FILE IFIPAT
5 FILE IMSDRUGNEWS
5 FILE IMSRESEARCH
13 FILE LIFSCI
31 FILE MEDLINE
17 FILE PASCAL
5 FILE PHAR
5 FILE PHIN
29 FILE PROMT
38 FILE SCISEARCH
68 FILE TOXCENTER
38 FILE USPATFULL
7 FILE USPAT2
64 FILES SEARCHED...

11 FILE WPIDS
11 FILE WPINDEX

33 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STINDEX

L1 QUE CHLOROTOXIN

=> s l1 and chemother?
1 FILE ADISINSIGHT
1 FILE BIOTECHNO
2 FILE CAPLUS
129 FILE DGENE
2 FILE EMBASE
2 FILE EMBIOBASE
1 FILE IFIPAT
1 FILE IMSDRUGNEWS
1 FILE IMSRESEARCH

1 FILE MEDLINE

48 FILES SEARCHED...
2 FILE PHAR
1 FILE PHIN
11 FILE PROMT
3 FILE TOXCENTER
16 FILE USPATFULL
4 FILE USPAT2
2 FILE WPIDS
2 FILE WPINDEX

18 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STINDEX

L2 QUE L1 AND CHEMOTHER?

=> b dgene caplus biotechno embase esbiobase ifipat medline prompt toxcenter uspatfull uspat2
wids wpindex
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE
ENTRY
2.44
TOTAL
SESSION
2.65

FILE 'DGENE' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CAPLUS' ENTERED AT 03:12:00 ON 09 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 03:12:00 ON 09 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'IFIPAT' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'MEDLINE' ENTERED AT 03:12:00 ON 09 JUN 2006

FILE 'PROMT' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 Gale Group. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 03:12:00 ON 09 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 03:12:00 ON 09 JUN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPINDEX' ENTERED AT 03:12:00 ON 09 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s l2
L3 174 L2

=> dup remo
ENTER L# LIST OR (END):l3
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4 163 DUP REMO L3 (11 DUPLICATES REMOVED)

--> s 14 and (bcnu or cisplatin or gemcitabine or hydroxyurea or paclitaxel or temozomide or topotecan or fluorouracil or vincristine or vinblastine or procarbazine or dacarbazine or altretamine)

15 8 FILES SEARCHED...

9 LA AND (BCNU OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR
PACLITAXEL OR TEMOZOMIDE OR TOPOTECAN OR FLUOROURACIL OR VINCRI
TINE OR VINBLASTINE OR PROCARBAZINE OR DACARBAZINE OR ALTRETAMINE
)

--> s 14 and (ciplatin or methotrexate or mercaptopurine or thioguanine or fludarabine or cladribine or pentostatin or cytarabine or azacitidine or vinblastine or etoposide or teniposide or irinotecan)

16 13 L4 AND (CIPLATIN OR METHOTREXATE OR MERCAPTOPYRINE OR THIIOUANI
NE OR FLUDARABINE OR CLADIRIBINE OR PENTOSTATIN OR CYTARABINE OR
AZACITIDINE OR VINBLASTINE OR ETOPOSIDE OR TENIPOSIDE OR IRINOTEC
AN)

--> s 14 and (docetaxel or doxorubicin or daunorubicin or dactinomycin or idarubicin or plicamycin or mitomycin or bleomycin or tamoxifen or flutamide or leuprolide or goserelin or aminoglutethimide)

17 13 L4 AND (DOCETAXEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOMYCI
N OR IDARUBICIN OR PLICAMYCIN OR MITOMYCIN OR BLEOMYCIN OR TAMOX
IFEN OR FLUTAMIDE OR LEUPROLIDE OR GOSERELIN OR AMINOGLUTETHIMIDE
)

--> s 14 and (anastrozole or amsacrine or asparaginase or mitoxantrone or mitotane or amifostine)

18 7 L4 AND (ANASTROZOLE OR AMSACRINE OR ASPARAGINASE OR MITOXANTRON
E OR MITOTANE OR AMIFOSTINE)

--> s 15 and 16 and 17 and 18

19 6 L5 AND L6 AND L7 AND L8

--> d 19 1-6 bib abs

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1154420 CAPLUS

DN 143:432633

TI Use of chlorotoxin in diagnosis and treatment of myeloid and lymphoid cell cancers

IN Alvarez, Vernon L.; Gonda, Matthew A.

PA Transmolecular, Inc., USA

SO PCT Int. Appl., 52 pp.

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2005099774 A2 20051027 WO 2005-US11523 20050406

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TE, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-559433P

AB Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or deriva., analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth. The chlorotoxin may be conjugated to a second protein.

e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific epitope, or a stabilizing protein such as human serum albumin. Alternatively, the chlorotoxin may be conjugated to a cytotoxic agent or chemotherapeutic agent.

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:971907 CAPLUS

DN 140:23219

TI Combination chemotherapy with chlorotoxin for treating cancer

IN Alvarez, Vermont L.; Grimes, Carol A.; Gonda, Matthew A.

PA Transmolecular, Inc., USA

SO PCT Int. Appl., 100 pp.

DT Patent

LA English

FAN.CNT 2

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2003101474 A1 20031211 WO 2003-US17410 20030602

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GR, HU, IE, IT, LT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MK, NE, SN, TD, TG

CA 2487425 AA 20031211 CA 2003-2487425 20030602

AU 2003240496 A1 20031219 AU 2003-240496 20030602

EP 1553962 A1 20050720 EP 2003-731504 20030602

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK, JP 2005537234 T2 20051208 JP 2004-508829 20030602

UP 2005088899 A1 20060427 US 2005-516079 20051102

PRAI US 2002-384171P P 20020531

WO 2003-US17410 W 20030602

AB This invention includes compns. and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof. A method for detecting the presence of cancer in a patient comprising administering a detectable amount of labeled chlorotoxin or chlorotoxin derivative are also claimed.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 6 IFIPAT COPYRIGHT 2006 IFI on STN

AN 1113983 IFIPAT:IFIUDS:IFICDB

TI COMBINATION CHEMOTHERAPY WITH CHLOROTOXIN

INF Alvarez, Vernon L.; Birmingham, AL, US

Gonda, Matthew A.; Birmingham, AL, US

Grimes, Carol A.; Birmingham, AL, US

Alvarez, Vernon L.; Gonda, Matthew A.; Grimes, Carol A.

PAF Unassigned

PA Unassigned Or Assigned To Individual (68000)

AG MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US

PI US 2006088899 A1 20060427

AI US 2003-516079 20030602

WO 2003-US17410 20030602

PRAI US 2002-384171P PCT 371 date

US 2002-406033P 20020531 (Provisional)

FI US 2006088899 20060427

DT Utility: Patent Application - First Publication

FS APPLICATION

PARN This application claims the benefit of U.S. Provisional Application

60/406,033 (filed Aug. 27, 2002) and U.S. Provisional Application 60/384,171 (filed May 31, 2002) both of which are hereby incorporated by reference in their entirety.

CLMN 17

OF 6 IFPAT COPYRIGHT 2006 IFI on STN

AB This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.

CLMN 17

L9 ANSWER 4 OF 6 USPATFULL on STN

AN 2005:234233 USPATFULL

TI PI-3 kinase inhibitor prodrugs

IN Durden, Joseph R., Westfield, IN, UNITED STATES

Patterson, Mary, Carmel, CA, UNITED STATES

Su, Jingdong, Westfield, IN, UNITED STATES

Subr, Robert G., Greenfield, IN, UNITED STATES

US 2005203173 AI 20050915

AI US 2005-111201 AI 20050420 (11)

RLI Continuation of Ser. No. US 2004-818145, filed on 5 Apr 2004, PENDING

PRAI US 2003-460137P 20030403 (60)

DT Utility

FS APPLICATION

LREP HOWREY LLP, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DR, SUITE

200, FALLS CHURCH, VA, 22042-2924, US

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 2848

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 6 USPATFULL on STN

AN 2005:105793 USPATFULL

TI Therapy via targeted delivery of nanoscale particles

IN Ivkov, Robert, Marblehead, MA, UNITED STATES

Daum, Wolfgang, Grotton, MA, UNITED STATES

Foreman, Allan, Epping, NH, UNITED STATES

Gwost, Douglas, Shoreview, MN, UNITED STATES

Triton Biosystems, Inc., Chelmsford, MA, UNITED STATES (U.S. corporation)

PA US 2005090732 AI 20050428

AI US 2003-696399 AI 20031028 (10)

DT Utility

FS APPLICATION

LREP PEPPER HAMILTON LLP, ONE MELLON CENTER, 50TH FLOOR, 500 GRANT STREET,

PITTSBURGH, PA, 15219, US

CLMN Number of Claims: 110

ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)

LN.CNT 2898

AB Disclosed are compositions, systems and methods for treating a subject's body, body part, tissue, body fluid cells, pathogens, or other undesirable matter involving the administration of a targeted chemotherapy that comprises a bioprobe (energy susceptible materials that are attached to a target-specific ligand). Such targeted therapy methods can be combined with at least one other therapy technique. Other therapies include hyperthermia, direct antibody therapy, radiation, chemo- or pharmaceutical therapy, photodynamic therapy, surgical or

interventional therapy, bone marrow or stem cell transplantation, and medical imaging, such as MRI, PET, SPECT, and bioimpedance. The disclosed therapies may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer, epitheloid sarcomas, AIDS, adverse angiogenesis, restenosis, amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque, obesity, malaria, and illnesses due to viruses, such as HIV.

L9 ANSWER 6 OF 6 USPATFULL on STN

AN 2004:307955 USPATFULL

TI PI-3 kinase inhibitor prodrugs

IN Garlich, Joseph R., Westfield, IN, UNITED STATES

Durden, Donald L., Decatur, GA, UNITED STATES

Patterson, Mary, Carmel, IN, UNITED STATES

Su, Jingdong, Westfield, IN, UNITED STATES

Subr, Robert G., Greenfield, IN, UNITED STATES

US 2004242631 AI 20041202

US 6949537 B2 20050927

AI US 2004-818145 AI 20040405 (10)

PRAI US 2003-460137P 20030403 (60)

DT Utility

FS APPLICATION

LREP HOWREY SIMON ARNOLD & WHITE, LLP, Attention: IP Prosecution, Box No. 34,

1299 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402

CLMN Number of Claims: 40

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN.CNT 3032

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPE, CROPU, DDFB, DDFE, DGENE, DISSABS, DRUGS, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:09:52 ON 09 JUN 2006

SEA CHLOROTOXIN

3 FILE ADISINSIGHT

5 FILE AGRICOLA

1 FILE ANABSTR

32 FILE BIOSIS

3 FILE BIOTECHABS

3 FILE BIOTECHDS

8 FILE BIOTECHNO

11 FILE CABA

41 FILE CAPLUS

1 FILE CEABA-VTB

8 FILE CIN

2 FILE DDFB

235 FILE DGENE

2 FILE DISSABS

2 FILE DRUGU

28 FILE EMBASE

22 FILE ESIIOBASE

1 FILE GENBANK

13 FILE IFPAT

9 FILE INSDRUGNEWS

5 FILE INMRESEARCH

13	FILE	LIFESC1
31	FILE	MEDLINE
17	FILE	PASCAL
5	FILE	PHAR
5	FILE	PHIN
29	FILE	PROMT
38	FILE	SCISEARCH
68	FILE	TOXCENF
38	FILE	USPATFUL
7	FILE	USPAT2
11	FILE	WPIDS
11	FILE	WPINDEX
		QUE
		CHLOROTOXIN

PRAI US 2004 -559433P P 20040406

AB Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivs.. analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth. The chlorotoxin may be conjugated to a second protein, e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific epitope, or a stabilizing protein such as human serum albumin. Alternatively, the chlorotoxin may be conjugated to a cytotoxic agent or chemotherapeutic agent.

L5 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS ON STN

AN 2003:971907 CAPLUS

DN 140:23219
TI Combination chemotherapy with chlorotoxin for treating

cancer

PA Transmolecular, Inc. USA

SO PCT Int. Appl., 100 pp.

DT CODEN: PIXXD2
Patent

LA English

FAN.CNT 2

PATENT - - - - -

PI WO 2003

 \ddot{z}

FILE 'DGENE, CAPLUS, BIOTECHNO, EMBASE, ESBIOBASE, IFIPAT, MEDLINE,
PROMT, TOXCENTER, USPATFULL, USPAT2, WPINDEX' ENTERED AT 03:12:00 ON 09
JUN 2006

4 S L2

3 DUP REMO L3 (11 DUPLICATES REMOVED)

b abs

OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
420 CAPLUS

3 Chlorotoxin in diagnosis and treatment of myeloid and cell cancers
Vernon L.; Gonda, Matthew A.
Mucular, Inc., USA
Appl., 52 pp.

chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof. A method for detecting the presence of cancer in a patient comprising administering a detectable amount of labeled chlorotoxin or chlorotoxin derivative are also claimed.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved.

```

AN      reserved on STN
200227256  FMRASE

```

TI Orathecin is active in pancreatic cancer patients.

SO Expert Review of Anticancer Therapy, (2002) Vol. 2, No. 2, pp. 137-140. .
ISSN: 1473-7140 CODEN: ERATBJ

CY United Kingdom
DT Journal; Note
FS 016 Cancer

027 Biophysics, Bioengineering and Medical Instrumentation
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
039 Pharmacy

LA English

ED Entered STN: 11 Jul 2002

Last Updated on STN: 11 Jul 2002

DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L5 ANSWER 4 OF 9 IFIPAT COPYRIGHT 2006 IFI on STN

AN 11139883 IFIPAT;IFIUDB;IFICDB

TI COMBINATION CHEMOTHERAPY WITH CHLOROTOXIN

INF Alvarez; Vernon L, Birmingham, AL, US

Gonda; Matthew A, Birmingham, AL, US

Grimes; Carol A, Birmingham, AL, US

IN Alvarez Vernon L; Gonda Matthew A; Grimes Carol A

PA Unassigned Or Assigned To Individual (68000)

AG MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC,

PI 200004, US

US 2006088899 A1 20060427

US 2003-516079 20030602

WO 2003-US17410 20030602

PRAI US 2002-384171P 20051102 PCT 371 date

US 2002-406033P 20020531 PCT 102(e) date

US 2006088899 20020827 (Provisional)

DT Utility; Patent Application - First Publication

FS CHEMICAL

PARN This application claims the benefit of U.S. Provisional Application

60/406,033 (filed Aug. 27, 2002) and U.S. Provisional Application

60/384,171 (filed May 31, 2002) both of which are hereby incorporated by

reference in their entirety.

CLMN 17

OF 9 IFIPAT COPYRIGHT 2006 IFI on STN

AB This invention includes compositions and methods for combination

chemotherapy, particularly involving at least one

chemotherapeutic agent used in combination with

chlorotoxin or a derivative thereof.

CLMN 17

L5 ANSWER 5 OF 9 PROMT COPYRIGHT 2006 Gale Group on STN

AN 2000:824983 PROMT

TI OTHER NEWS TO NOTE.

SO BLOWORLD Today, (22 Sep 2000) Vol. 11, No. 184.

FB American Health Consultants, Inc.

DT Newsletter

LA English

WC 1452

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB Aysa Pharmaceuticals Inc., of South San Francisco, said it agreed to

sell \$26 million aggregate principal amount of 8 percent senior secured

convertible notes maturing on Oct. 1, 2004. Aysa previously announced its

intention to sell up to \$20 million of fixed rate convertible notes. Diaz

& Altschul Capital LLC served as placement agent for the transaction.

(See Bloworld Today, Sept. 19, 2000, p. 1.)

THIS IS THE FULL TEXT: COPYRIGHT 2000 American Health Consultants, Inc.

Subscription: \$1350.00 per year. Published daily (5 times a week).

L5 ANSWER 6 OF 9 USPATFULL on STN

AN 2005:234233 USPATFULL

TI PI-3 Kinase Inhibitor Prodrugs

IN Garlich, Joseph R., Westfield, IN, UNITED STATES

Durden, Donald L., Decatur, GA, UNITED STATES

Patterson, Mary, Carmel, IN, UNITED STATES

Su, Jingdong, Westfield, IN, UNITED STATES

Suhr, Robert G., Greenfield, IN, UNITED STATES

PI US 2005203173 A1 20050915

US 2005-111201 A1 20050420 (11)

RUL Continuation of Ser. No. US 2004-818145, filed on 5 Apr 2004, PENDING

PRAI US 2003-460137P 20030403 (60)

DT Utility

FS APPLICATION

LREP HOWREY LLP, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DR, SUITE

200, FALLS CHURCH, VA, 22042-2924, US

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN 8 Drawing Page(s)

LN CNT 2848

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The

novel compounds are LY294002 and analogs thereof comprising a reversibly

quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 9 USPATFULL on STN

AN 2005:105793 USPATFULL

TI Therapy via targeted delivery of nanoscale particles

IN Ivkov, Robert, Marblehead, MA, UNITED STATES

Daum, Wolfgang, Grotton, MA, UNITED STATES

Foreman, Allan, Epping, NH, UNITED STATES

Gwoost, Douglas, Shoreview, MN, UNITED STATES

Triton Biosystems, Inc., Chelmsford, MA, UNITED STATES (U.S.

corporation)

PI US 2005090732 A1 20050428

US 2003-696399 A1 20031028 (10)

DT Utility

FS APPLICATION

LREP PEPPER HAMILTON LLP, ONE MELLON CENTER, 50TH FLOOR, 500 GRANT STREET,

PITTSBURGH, PA, 15219, US

CLMN Number of Claims: 110

ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)

LN CNT 2898

AB Disclosed are compositions, systems and methods for treating a subject's

body, body part, tissue, body fluid cells, pathogens, or other

undesirable matter involving the administration of a targeted

thermotherapy that comprises a bioprobe (energy susceptible materials

that are attached to a target-specific ligand). Such targeted therapy

methods can be combined with at least one other therapy technique. Other

therapies include hyperthermia, direct antibody therapy, radiation,

chemo- or pharmaceutical therapy, photodynamic therapy, surgical or

interventional therapy, bone marrow or stem cell transplantation, and

medical imaging, such as MRI, PET, SPECT, and bioimpedance. The

disclosed therapies may be useful in the treatment of a variety of

indications, including but not limited to, cancer of any type, such as

bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate

cancer, epithelial sarcomas, AIDS, adverse angiogenesis, restenosis,

amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque,

obesity, malaria, and illnesses due to viruses, such as HIV.

L5 ANSWER 8 OF 9 USPATFULL on STN

AN 2004:307955 USPATFULL

TI PI-3 Kinase Inhibitor Prodrugs

IN Garlich, Joseph R., Westfield, IN, UNITED STATES

Durden, Donald L., Decatur, GA, UNITED STATES

Patterson, Mary, Carmel, IN, UNITED STATES
Su, Jindong, Westfield, IN, UNITED STATES
Suhr, Robert G., Greenfield, IN, UNITED STATES
PI US 2004244631 A1 20041202
US 6949537 B2 20050927
AI US 2004-818145 A1 20040405 (10)
PRAI US 2003-460137P 20030403 (60)
DT Utility
FS APPLICATION
LREP HOWREY SIMON ARNOLD & WHITE, LLP, Attention: IP Prosecution, Box No. 34,
1299 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN CNT 3032

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 9 USPTAFULL on STN
AN 2004.197463 USPTAFULL
TI Modified carbamate-containing prodrugs and methods of synthesizing same
IN Kwuribe, Nnochiri Nkem, Cary, NC, UNITED STATES
Riggs-Sauthier, Jennifer, Raleigh, NC, UNITED STATES
Dyakonov, Tatyana A., Durham, NC, UNITED STATES
PI US 2004152769 A1 20040805
AI US 2003-703647 A1 20031107 (10)
PRAI US 2002-424796P 20021109 (60)
US 2003-483676P 20030630 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGSEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN CNT 2938

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Prodrugs having a hydrolyzable carbamate moiety, compositions including the prodrugs, methods of preparing the prodrugs and methods of treatment using the prodrugs are disclosed. The prodrug has the formula DC(X)XR, where D is a biologically active agent, X is O, S or NR', and R is a moiety that modifies various properties of the biologically active agent. The biologically active agent either includes a functional group such as an amide, thioamide, imide, thioimide, urea, thiourea, carbamate, thiocarbamate, sulfonamide, or sulfonimide group, or includes a hydroxy, amine, carboxylic acid or thiol group that is modified to include such a group. An NH group from the biologically active agent can be coupled to an activated form of the C(X)XR moiety to form the prodrugs described herein. Relative to a conventional carbamate group, the presence of the additional carbonyl or sulfonyl group makes the carbamate group more susceptible to hydrolysis. The prodrugs are more stable in certain environments than the biologically active agent, and can permit the drugs to be administered orally, in those embodiments where the biologically active agent must otherwise be administered by injection or intravenous administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

--> d his

(FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIENG, BIOSIS, BIOTECHS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,

DRUGMONOG2, DRUGU, EMBAL, EMBASE, ... ENTERED AT 03:09:52 ON 09 JUN 2006
SEA CHLOROTOXIN

3 FILE ADISINSIGHT
5 FILE AGRICOLA
1 FILE ANABSTR
32 FILE BIOSIS
3 FILE BIOTECHABS
3 FILE BIOTECHDS
8 FILE BIOTECHNO
11 FILE CABA
41 FILE CAPLUS
1 FILE CEABA-VTB
8 FILE CIN
2 FILE DDFU
235 FILE DGENE
2 FILE DISSABS
2 FILE DRUGU
28 FILE EMBASE
22 FILE ESIORBASE
1 FILE GENBANK
13 FILE IFIPAT
9 FILE IMSDRUGNEWS
5 FILE IMSRESEARCH
13 FILE LIFESCI
31 FILE MEDLINE
17 FILE PASCAL
5 FILE PHAR
5 FILE PHIN
29 FILE PROMT
36 FILE SCISEARCH
68 FILE TOXCENTER
38 FILE USPTAFULL
7 FILE USPAT2
11 FILE WPIDS
11 FILE WPINDEX
QUE CHLOROTOXIN

L1

SEA L1 AND CHEMOTHER?

1 FILE ADISINSIGHT
1 FILE BIOTECHNO
2 FILE CAPLUS
129 FILE DGENE
2 FILE EMBASE
2 FILE ESIORBASE
1 FILE IFIPAT
1 FILE IMSDRUGNEWS
1 FILE IMSRESEARCH
1 FILE MEDLINE
2 FILE PHAR
1 FILE PHIN
11 FILE PROMT
3 FILE TOXCENTER
16 FILE USPTAFULL
4 FILE USPAT2
2 FILE WPIDS
2 FILE WPINDEX
QUE L1 AND CHEMOTHER?

L2

FILE 'DGENE, CAPLUS, BIOTECHNO, EMBASE, ESIORBASE, IFIPAT, MEDLINE, PROMT, TOXCENTER, USPTAFULL, USPAT2, WPINDEX' ENTERED AT 03:12:00 ON 09 JUN 2006

174 S L2

163 DUP REMO L3 (11 DUPLICATES REMOVED)

9 S L4 AND (BCNU OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR P
13 S L4 AND (CISPLATIN OR METHOTREXATE OR MERCAPTOPURINE OR THIQU
13 S L4 AND (DOCEFAXEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOM

L3

L4

L5

L6

L7

L8 7 S L4 AND (ANASTROZOLE OR AMSACRINE OR ASPARAGINASE OR MITOXANT
L9 6 S L5 AND L6 AND L7 AND L8

--> d 16 1-13 bib abs

L6 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1154420 CAPLUS
DN 143:432633
TI Use of chlorotoxin in diagnosis and treatment of myeloid and
lymphoid cell cancers
IN Alvarez, Vernon L.; Gonda, Matthew A.
PA Transmolecular, Inc., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXD2
DT Patent
LA English
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005099774	A2	20051027	WO 2005-US11523	20050406
W:	A3	20060323		
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-559433P P 20040406
AB Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivs., analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth. The chlorotoxin may be conjugated to a second protein, e.g., an antibody binding to a myeloid or lymphoid cancer cell-specific epitope, or a stabilizing protein such as human serum albumin. Alternatively, the chlorotoxin may be conjugated to a cytotoxic agent or chemotherapeutic agent.

L6 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:971907 CAPLUS
DN 140:23219
TI Combination chemotherapy with chlorotoxin for treating cancer
IN Alvarez, Vermont L.; Grimes, Carol A.; Gonda, Matthew A.
PA Transmolecular, Inc., USA
SO PCT Int. Appl., 100 pp.
CODEN: PIXD2
DT Patent
LA English
FAN CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003101474	A1	20031211	WO 2003-US17410	20030602
W:	A2			
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

CA 2487425 AA 20031211 CA 2003-2487425 20030602
AU 2003240496 A1 20031219 AU 2003-240496 20030602
EP 1553962 A1 20050720 EP 2003-731504 20030602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005537234 T2 20051208 JP 2004-508829 20030602
US 2006088899 A1 20060427 US 2005-516079 20051102
PRAI US 2002-384171P P 20020531
US 2002-406033P P 20020827
WO 2003-US17410 W 20030602
AB This invention includes compns. and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof. A method for detecting the presence of cancer in a patient comprising administering a detectable amount of labeled chlorotoxin or chlorotoxin derivative are also claimed.

RE CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 13 IFIPAT COPYRIGHT 2006 IFI on STN
AN 1113983 IFIPAT:IFIUDS:IFICDB
TI COMBINATION CHEMOTHERAPY WITH CHLOROTOXIN
IN Alvarez, Vernon L.; Birmingham, AL, US
Gonda, Matthew A.; Birmingham, AL, US
Grimes, Carol A.; Birmingham, AL, US
IN Alvarez, Vernon L.; Gonda, Matthew A.; Grimes, Carol A. Unassigned
PA Unassigned or Assigned To Individual (68000)
AG MORGAN LEWIS & BOKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
PI US 2006088899 A1 20060427
AI US 2003-516079 20030602
WO 2003-US17410 20030602

PRAI US 2002-384171P 20020531 PCT 371 date
US 2002-406033P 20020827 PCT 102(e) date
FI US 2006088899 20060427 (Provisional)
DT Utility; Patent Application - First Publication
FS CHEMICAL APPLICATION
PARN This application claims the benefit of U.S. Provisional Application 60/406,033 (filed Aug. 27, 2002) and U.S. Provisional Application 60/384,171 (filed May 31, 2002) both of which are hereby incorporated by reference in their entirety.

CLMN 17
OF 13 IFIPAT COPYRIGHT 2006 IFI on STN
AB This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.

CLMN 17
L6 ANSWER 4 OF 13 USPATFULL on STN
AN 2005:234233 USPATFULL
TI PI-3 Kinase inhibitor prodrgs
IN Durden, Joseph R.; Westfield, IN, UNITED STATES
Gardich, Joseph R.; Westfield, IN, UNITED STATES
Patterson, Mary; Carmel, GA, UNITED STATES
Su, Jingdong; Westfield, IN, UNITED STATES
Suhr, Robert G.; Greenfield, IN, UNITED STATES
US 2005203173 A1 20050915
AI US 2005-111201 20050420 (11)
RLI Continuation of Ser. No. US 2004-818145, filed on 5 Apr 2004, PENDING
PRAI US 2003-460137P 20030403 (60)
DT Utility
FS APPLICATION
LREP HOWREY LLP, C/O IP DOCKETING DEPARTMENT, 2941 FAIRVIEW PARK DR, SUITE

200, FALLS CHURCH, VA, 22042-2924, US

CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2848

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides novel prodrgs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 13 USPATFULL on STN

AN 2005-215483 USPATFULL

TI Protection of endogenous therapeutic peptides from peptidase activity

IN Through conjugation to blood components

Bridon, Dominique P., Ville Mont-Royal, CANADA

Erin, Alan M., Moraga, CA, UNITED STATES

Milner, Peter G., Los Altos, CA, UNITED STATES

Holmes, Darren L., Montreal, CANADA

Thibadeau, Karen, Montreal, CANADA

PA ConjuChem, Inc., Montreal, CANADA (non-U.S. corporation)

PI US 2005187159 A1 20050825

AI US 2005-66697 A1 20050225 (11)

RLI Continuation of Ser. No. US 2000-657276, filed on 7 Sep 2000, GRANTED, Pat. No. US 6887470

PRAI US 1999-153406P 19990910 (60)

US 1999-159783P 19991015 (60)

DT Utility

FS APPLICATION

LREP MORRISON & FOERSTER LLP, 425 MARKET STREET, SAN FRANCISCO, CA, 94105-2482, US

CLMN Number of Claims: 29

ECL Exemplary Claim: 1-26

DRWN No Drawings

LN.CNT 5233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 13 USPATFULL on STN

AN 2005-107237 USPATFULL

TI Protection of endogenous therapeutic peptides from peptidase activity

IN Through conjugation to blood components

Bridon, Dominique P., Outremont, CANADA

Erin, Alan M., Moraga, CA, UNITED STATES

Milner, Peter G., Los Altos Hills, CA, UNITED STATES

Holmes, Darren L., Montreal, CANADA

Thibadeau, Karen, Montreal, CANADA

PA ConjuChem, Inc., Montreal, CANADA (non-U.S. corporation)

PI US 6887470 B1 20050503

AI US 2000-657276 20000907 (9)

US 1999-159783P 19991015 (60)

PRAI US 1999-153406P 19990910 (60)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Snedden, Sheridan

LREP Morrison & Foerster LLP

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 5136

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 13 USPATFULL on STN

AN 2005-105793 USPATFULL

TI Therapy via targeted delivery of nanoscale particles

IN Ivkov, Robert, Marblehead, MA, UNITED STATES

Dam, Wolfgang, Grotton, MA, UNITED STATES

Foreman, Allan, Epping, NH, UNITED STATES

Gwost, Douglas, Shoreview, MN, UNITED STATES

PA Triton Biosystems, Inc., Chelmsford, MA, UNITED STATES (U.S. corporation)

PI US 2005090732 A1 20050428

AI US 2003-696399 A1 20031028 (10)

DT Utility

FS APPLICATION

LREP PEPPER HAMILTON LLP, ONE MELLON CENTER, 50TH FLOOR, 500 GRANT STREET, PITTSBURGH, PA, 15219, US

CLMN Number of Claims: 110

ECL Exemplary Claim: 1

DRWN 12 Drawing Page(s)

LN.CNT 2898

AB Disclosed are compositions, systems and methods for treating a subject's body, body part, tissue, body fluid cells, pathogens, or other undesirable matter involving the administration of a targeted chemotherapy that comprises a bioprobe (energy susceptible materials that are attached to a target-specific ligand). Such targeted therapy methods can be combined with at least one other therapy technique. Other therapies include hyperthermia, direct antibody therapy, radiation, chemo- or pharmaceutical therapy, photodynamic therapy, surgical or interventional therapy, bone marrow or stem cell transplantation, and medical imaging, such as MRI, PET, SPECT, and bioimpedance. The disclosed therapies may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer, epithelial sarcomas, AIDS, adverse angiogenesis, restenosis, amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque, obesity, malaria, and illnesses due to viruses, such as HIV.

L6 ANSWER 8 OF 13 USPATFULL on STN

AN 2005-26381 USPATFULL

TI Protection of endogenous therapeutic peptides from peptidase activity

IN Through conjugation to blood components

Bridon, Dominique P., Outremont, CANADA

Ezrin, Alan M., Moraga, CA, United States
Milner, Peter G., Los Altos Hills, CA, United States
Holmes, Darren L., Montreal, CANADA
Thibodeau, Karen, Montreal, CANADA
Conjuchem, Inc., Montreal, CANADA (non-U.S. corporation)
FI US 6849714 B1 20050201
WO 2000069900 20001123
AI US 2000-623548
WO 2000-US13576 20000905 (9)
WO 2000-US13576 20000517
PRAI US 1999-134406P 19990517 (60) PCT 371 date
US 1999-153406P 19990910 (60)
US 1999-159783P 19991015 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Desai, Anand
LREP Morrison & Foerster LLP
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 5180

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of synthesizing a modified therapeutic peptide capable of forming a peptidase-stabilized therapeutic peptide conjugate, the peptide having between 3 and 50 amino acids, is k. In a first step of the method, a therapeutic peptide having a carboxy terminal amino acid and amino terminal amino acid is synthesized. In a second step, pairs of cysteine residues present in the therapeutic peptide are sequentially and selectively oxidized to form disulfide bridges in the therapeutic peptide. In a third step, a protecting group is attached to remaining cysteine residues that do not form disulfide bridges in the therapeutic peptide. Finally, the peptide is coupled to a reactive group capable of reacting with amino groups, hydroxyl groups or thiol groups on a blood component to form a covalent bond therewith.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 13 USPTATFULL on STN
AN 2004:307955 USPTATFULL
TI PI-3 kinase inhibitor prodrugs
IN Durden, Joseph R., Westfield, IN, UNITED STATES
Gurden, Donald L., Decatur, GA, UNITED STATES
Patterson, Mary, Carmel, IN, UNITED STATES
Su, Jingdong, Westfield, IN, UNITED STATES
Sunr, Robert G., Greenfield, IN, UNITED STATES
US 2004242631 A1 20041202
US 6949537 B2 20050927
AI US 2004-818145 A1 20040405 (10)
PRAI US 2003-460137P 20030403 (60)
DT Utility
FS APPLICATION
LREP HOWREY SIMON ARNOLD & WHITE, LLP, Attention: IP Prosecution, Box No. 34,
1299 Pennsylvania Avenue, N.W., Washington, DC, 20004-2402
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3032

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 13 USPTATFULL on STN
AN 2004:197463 USPTATFULL
TI Modified carbanate-containing prodrugs and methods of synthesizing same
IN Ekwuribe, Nnochiri Nkem, Cary, NC, UNITED STATES

Riggs-Sauthier, Jennifer, Raleigh, NC, UNITED STATES
Dyakonov, Tatyana A., Durham, NC, UNITED STATES
US 2004152769 A1 20040805
AI US 2003-703647 A1 20031107 (10)
PRAI US 2002-424796P 20021109 (60)
US 2003-483676P 20030630 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 2938

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Prodrugs having a hydrolyzable carbamate moiety, compositions including the prodrugs, methods of preparing the prodrugs and methods of treatment using the prodrugs are disclosed. The prodrug has the formula DC(X)XR, where D is a biologically active agent, X is O, S or NR', and R is a moiety that modifies various properties of the biologically active agent. The biologically active agent either includes a functional group such as an amide, thioamide, imide, thioimide, urea, thiourea, carbamate, thiocarbamate, sulfonamide, or sulfonimide group, or includes a hydroxy, amine, carboxylic acid or thiol group that is modified to include such a group. An NH group from the biologically active agent can be coupled to an activated form of the C(X)XR moiety to form the prodrugs described herein. Relative to a conventional carbamate group, the presence of the additional carbonyl or sulfonyl group makes the carbamate group more susceptible to hydrolysis. The prodrugs are more stable in certain environments than the biologically active agent, and can permit the drugs to be administered orally, in those embodiments where the biologically active agent must otherwise be administered by injection or intravenous administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 13 USPTATFULL on STN
AN 2004:23553 USPTATFULL
TI Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
IN Soltero, Richard, Holly Springs, NC, UNITED STATES
Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES
Opawaite, Foyete, Raleigh, NC, UNITED STATES
Renlaender, Bruce, Chapel Hill, NC, UNITED STATES
Hickey, Anthony, Chapel Hill, NC, UNITED STATES
Bovet, Li Li, Chapel Hill, NC, UNITED STATES
US 2004017387 A1 20040129
US 7030082 B2 20060418
AI US 2003-382069 A1 20030305 (10)
RLI Continuation-in-part of Ser. No. US 2002-235281, filed on 5 Sep 2002,
PENDING Continuation-in-part of Ser. No. US 2002-235284, filed on 5 Sep 2002,
2002, PENDING
PRAI US 2001-318193P 20010907 (60)
US 2002-377865P 20020503 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 80
ECL Exemplary Claim: 1
DRWN 19 Drawing Page(s)
LN.CNT 3722

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1 or any value between. Methods of treating diseases in a subject in need of such treatment using the pharmaceutical compositions of this invention are also

provided, as well as methods of providing such pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 13 USPATFULL on STN
AN 2003:306886 USPATFULL
TI Peptides for recognition and targeting of GLIAL cell tumors
IN Petrenko, Valery A., Auburn, AL, UNITED STATES
Cox, Nancy R., Auburn, AL, UNITED STATES
Morrison, Nancy E., Auburn, AL, UNITED STATES
Baker, Henry J., Auburn, AL, UNITED STATES
Globe, Ludmila F., Auburn, AL, UNITED STATES
Auburn University (U.S. corporation)
PA US 2003:216322 AI 20031120
FI US 2003-357929 AI 20030204 (10)
PRAI US 2002-354118P 20020204 (60)
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 1835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions for use in characterization, diagnosis, prognosis, and therapy of cancer cells are provided. The compositions comprise peptides and variants thereof which were isolated based on their ability to selectively bind glioma cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 13 USPATFULL on STN
AN 2003:100060 USPATFULL
TI Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
IN Soltero, Richard, Holly Springs, NC, UNITED STATES
Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES
Opavale, Foye, Raleigh, NC, UNITED STATES
Rehlander, Bruce, Chapel Hill, NC, UNITED STATES
Hickey, Anthony, Chapel Hill, NC, UNITED STATES
Li Li, Bovet, Chapel Hill, NC, UNITED STATES
PI US 2003069170 AI 20030410
US 6770625 B2 20040803
AI US 2002-235284 AI 20020905 (10)
PRAI US 2001-318193P 20010907 (60)
US 2002-377865P 20020503 (60)
DT Utility
FS APPLICATION
LREP MYERS BIGEL SIBLEY & SAJOVEC, PO BOX 37428, RALEIGH, NC, 27627
CLMN Number of Claims: 130
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 3615
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 03:09:16 ON 09 JUN 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGS, DRUGMONO2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 03:09:52 ON 09 JUN 2006
DRUGMONO2, SEA CHLOROTOXIN

3 FILE ADISINSIGHT
5 FILE AGRICOLA
1 FILE ANABSTR
32 FILE BIOSIS
3 FILE BIOTECHABS
3 FILE BIOTECHDS
8 FILE BIOTECHNO
11 FILE CABA
41 FILE CAPLUS
1 FILE CEABA-VTB
8 FILE CIN
2 FILE DDFB
235 FILE DGENE
2 FILE DISSABS
2 FILE DRUGU
28 FILE EMBASE
22 FILE ESIIOBASE
1 FILE GENBANK
13 FILE IFIPAT
9 FILE IMSDRUGNEWS
5 FILE IMSRESEARCH
13 FILE LIFESCI
31 FILE MEDLINE
17 FILE PASCAL
5 FILE PHAR
5 FILE PHIN
29 FILE PROMT
38 FILE SCISEARCH
68 FILE TOXCENTER
38 FILE USPATFULL
7 FILE USPAT2
11 FILE WPIDS
11 FILE WPINDEX
11 FILE WPINDEX

SEA L1 AND CHEMOTHER?

L1

1 FILE ADISINSIGHT
1 FILE BIOTECHNO
2 FILE CAPLUS
129 FILE DGENE
2 FILE EMBASE
2 FILE ESIIOBASE
1 FILE IFIPAT
1 FILE IMSDRUGNEWS
1 FILE IMSRESEARCH
1 FILE MEDLINE
2 FILE PHAR
2 FILE PHIN
11 FILE PROMT
16 FILE TOXCENTER
4 FILE USPATFULL
4 FILE USPAT2
2 FILE WPIDS
2 FILE WPINDEX

QUE L1 AND CHEMOTHER?

L2

FILE 'DGENE, CAPLUS, BIOTECHNO, EMBASE, ESIIOBASE, IFIPAT, MEDLINE, PROMT, TOXCENTER, USPATFULL, USPAT2, WPINDEX' ENTERED AT 03:12:00 ON 09

JUN 2006

L3 174 S L2
L4 163 DUP REMO L3 (11 DUPLICATES REMOVED)
L5 9 S L4 AND (HCNU OR CISPLATIN OR GEMCITABINE OR HYDROXYUREA OR P
L6 13 S L4 AND (CISPLATIN OR METHOTREXATE OR MERCAPTOPYRINE OR THIOPU
L7 13 S L4 AND (DOCETAXEL OR DOXORUBICIN OR DAUNORUBICIN OR DACTINOM
L8 7 S L4 AND (ANASTROZOLE OR AMSACRINE OR ASPARAGINASE OR MITOXANT
L9 6 S L5 AND L6 AND L7 AND L8